Guggenheim initiated coverage on Freeline Therapeutics with a new price target

Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline's GBA1 Parkinson's disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the acceptance of multiple abstracts, including one for a late-breaking oral presentation on new clinical data from its Gaucher disease program, at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland. "Gaucher disease is a severe and progressive disorder that leads to a wide range of symptoms, including enlarged organs, bone pain and fractures, low bl

LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that, in connection with Syncona's acquisition of Freeline by way of a scheme of arrangement (the "Scheme"), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the "Scheme Circular") has been delivered to the Registrar of Companies.   Accordingly, the Scheme has become Effective in accordance with its terms and the entire issued share capital of Freeline is now owned or controlled by Syncona Portfolio Limited. Capitalized terms in this an

LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that Freeline's shareholders have approved the proposal for Bidco 1354 Limited ("Bidco"), a wholly owned subsidiary of Syncona Portfolio Limited ("Syncona Portfolio"), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share ("ADS") in cash (the "Acquisition"). As previously announced, Freeline and Bidco entered into an implementation agreement on November 22, 2023 to implement the Acquisition by means of a scheme of arrangement pursuant to Part 26 of the UK Companies Act 2006 (the "Sche

Morgan Stanley downgraded Freeline Therapeutics from Overweight to Equal-Weight

Redburn upgraded Freeline Therapeutics from Neutral to Buy

BTIG initiated coverage of Freeline Therapeutics with a rating of Buy and set a new price target of $10.00

15-12G - Freeline Therapeutics Holdings plc (0001810031) (Filer)

EFFECT - Freeline Therapeutics Holdings plc (0001810031) (Filer)

S-8 POS - Freeline Therapeutics Holdings plc (0001810031) (Filer)

Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins Genespire to accelerate pipeline to the clinic Milan, Italy, 7 July 2022: Genespire, a next generation gene therapy company developing first-in-class transformative therapies with advanced lentiviral vectors, today announces the appointment of Dr. Sabah Sallah MD, PhD as Chief Medical Officer. Dr. Sallah will lead the Company's clinical strategy, development and operations as Genespire progresses its novel advanced lentiviral gene therapy platforms towards the clinic. Dr. Sallah is a board-certified hematologist who has spent more than

LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline") today announced that Paul M. Schneider has been appointed Chief Financial Officer (CFO), effective May 16, 2022, based in Boston. Mr. Schneider joins Freeline from Exo Therapeutics, Inc., where he served as Senior Vice President, Finance and Operations. A seasoned financial executive with more than 20 years of leadership experience in large and small private and public biopharmaceutical companies, Mr. Schneider brings an impressive track record of financial stewardship, including corporate strategy and execution, financial planning, analysis and reporting, and investor

LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative adeno-associated virus ("AAV") vector-mediated systemic gene therapies for people with inherited systemic debilitating diseases, today announced the expansion of its executive leadership team with the appointment of Henning R. Stennicke, PhD, as Chief Scientific Officer (CSO). Dr. Stennicke has been appointed to the role of CSO effective March 1, 2022. He will be based in Stevenage, UK, and report to Michael Parini, Freeline's Chief Executive Officer, as part of the executive leadership team. As CSO, Dr.

Robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma FLT201 has been well tolerated, with no serious adverse events Company to host conference call today at 8 a.m. ET LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease. Gaucher disease is a debilitatin

Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase variant with research program for GBA1-linked Parkinson's disease Management to host conference call at 8:00 a.m. ET today LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported financial results for the second quarter of 2023 and provided a business update. "FLT201 is a potential first- and best-in-class gene therapy for Gaucher disease Type 1, the most common type of the disease," said Michael Parini, Chief Exec

LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update. Participants may access this event via the teleconferencing numbers below and asking to join the Freeline call or through the webcast link here. Domestic: 1-866-524-3160International: 1-412-317-6760 While not required, it is recommended that participants join the call 10 minutes prior to the scheduled start. A live webcast of the call will also be available on the Investors section of Freeline's website at ww

SC 13D/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)

SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)

SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)